Astellas Pharma (ALPMY) Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Astellas Pharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Astellas Pharma stock.
View analyst ratings for Astellas Pharma or view top-rated stocks.

Astellas Pharma's stock was trading at $16.27 at the start of the year. Since then, ALPMY shares have decreased by 8.1% and is now trading at $14.96.
View the best growth stocks for 2022 here.

Astellas Pharma saw a decrease in short interest in July. As of July 15th, there was short interest totaling 66,800 shares, a decrease of 63.5% from the June 30th total of 183,100 shares. Based on an average trading volume of 144,000 shares, the days-to-cover ratio is presently 0.5 days.
View Astellas Pharma's Short Interest.

Astellas Pharma Inc. (OTCMKTS:ALPMY) posted its quarterly earnings data on Tuesday, April, 27th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.22 by $0.28. The firm had revenue of $2.91 billion for the quarter. Astellas Pharma had a net margin of 8.91% and a trailing twelve-month return on equity of 8.62%.

Astellas Pharma(OTCMKTS:ALPMY) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.83%. The dividend payout ratio of Astellas Pharma is 49.09%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Astellas Pharma will have a dividend payout ratio of 27.84% next year. This indicates that Astellas Pharma will be able to sustain or increase its dividend.

Astellas Pharma's stock split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were payable to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of Astellas Pharma stock prior to the split would have 125 shares after the split.

Astellas Pharma trades on the OTCMKTS under the ticker symbol "ALPMY."

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALPMY stock can currently be purchased for approximately $14.96.

Astellas Pharma (OTCMKTS:ALPMY) has a market capitalization of $27.46 billion and generates $11.55 billion in revenue each year. The company earns $1.10 billion in net income (profit) each year or $0.55 on an earnings per share basis.

Astellas Pharma employs 15,455 workers across the globe.

Astellas Pharma was founded in 1923.

Astellas Pharma's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The official website for Astellas Pharma is www.astellas.com. The company can be reached via phone at (133) 244-3000.